These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 22974428)
1. Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer. Tanaka N; Asakawa I; Fujimoto K; Anai S; Hirayama A; Hasegawa M; Konishi N; Hirao Y BMC Urol; 2012 Sep; 12():28. PubMed ID: 22974428 [TBL] [Abstract][Full Text] [Related]
2. PSA bounce predicts early success in patients with permanent iodine-125 prostate implant. Patel C; Elshaikh MA; Angermeier K; Ulchaker J; Klein EA; Chehade N; Wilkinson DA; Reddy CA; Ciezki JP Urology; 2004 Jan; 63(1):110-3. PubMed ID: 14751360 [TBL] [Abstract][Full Text] [Related]
4. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer. Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022 [TBL] [Abstract][Full Text] [Related]
5. Long-term prognostic significance of rising PSA levels following radiotherapy for localized prostate cancer - focus on overall survival. Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M Radiat Oncol; 2017 Jun; 12(1):98. PubMed ID: 28615058 [TBL] [Abstract][Full Text] [Related]
6. Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated radiation therapy for prostate cancer. Tanaka N; Asakawa I; Nakai Y; Miyake M; Anai S; Fujii T; Hasegawa M; Konishi N; Fujimoto K BMC Cancer; 2017 Aug; 17(1):573. PubMed ID: 28841855 [TBL] [Abstract][Full Text] [Related]
7. Racial differences in the PSA bounce in predicting prostate cancer outcomes after brachytherapy: Evidence from the Department of Veterans Affairs. Slade AN; Dahman B; Chang MG Brachytherapy; 2020; 19(1):6-12. PubMed ID: 31611160 [TBL] [Abstract][Full Text] [Related]
9. Salvage brachytherapy for recurrent prostate cancer after definitive radiation therapy: A comparison of low-dose-rate and high-dose-rate brachytherapy and the importance of prostate-specific antigen doubling time. Kollmeier MA; McBride S; Taggar A; Anderson E; Lin M; Pei X; Weiji S; Voros L; Cohen G; Yamada Y; Zelefsky MJ Brachytherapy; 2017; 16(6):1091-1098. PubMed ID: 28838648 [TBL] [Abstract][Full Text] [Related]
10. PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. Crook J; Gillan C; Yeung I; Austen L; McLean M; Lockwood G Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):426-33. PubMed ID: 17869662 [TBL] [Abstract][Full Text] [Related]
11. Good prognosis following a PSA bounce after high dose rate brachytherapy and external radiotherapy in prostate cancer. Åström L; Sandin F; Holmberg L Radiother Oncol; 2018 Dec; 129(3):561-566. PubMed ID: 30193693 [TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Stock RG; Stone NN; Cesaretti JA Int J Radiat Oncol Biol Phys; 2003 Jun; 56(2):448-53. PubMed ID: 12738319 [TBL] [Abstract][Full Text] [Related]
13. Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer. Kanai K; Nakashima J; Sugawara A; Shigematsu N; Nagata H; Kikuchi E; Miyajima A; Nakagawa K; Kubo A; Oya M Int J Clin Oncol; 2009 Dec; 14(6):502-6. PubMed ID: 19967485 [TBL] [Abstract][Full Text] [Related]
14. PSA bounce after prostate brachytherapy with or without neoadjuvant androgen deprivation. McGrath SD; Antonucci JV; Fitch DL; Ghilezan M; Gustafson GS; Vicini FA; Martinez AA; Kestin LL Brachytherapy; 2010; 9(2):137-44. PubMed ID: 19850537 [TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen bounce after high-dose-rate prostate brachytherapy and hypofractionated external beam radiotherapy. Patel N; Souhami L; Mansure JJ; Duclos M; Aprikian A; Faria S; David M; Cury FL Brachytherapy; 2014; 13(5):450-5. PubMed ID: 25023396 [TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. Critz FA; Williams WH; Levinson AK; Benton JB; Schnell FJ; Holladay CT; Shrake PD J Urol; 2003 Nov; 170(5):1864-7. PubMed ID: 14532794 [TBL] [Abstract][Full Text] [Related]
17. PSA bounce after ¹²⁵I-brachytherapy for prostate cancer as a favorable prognosticator. Engeler DS; Schwab C; Thöni AF; Hochreiter W; Prikler L; Suter S; Stucki P; Schiefer J; Plasswilm L; Schmid HP; Putora PM Strahlenther Onkol; 2015 Oct; 191(10):787-91. PubMed ID: 26100965 [TBL] [Abstract][Full Text] [Related]
18. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients. Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782 [TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival. Lo AC; Morris WJ; Lapointe V; Hamm J; Keyes M; Pickles T; McKenzie M; Spadinger I Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):87-93. PubMed ID: 24331654 [TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen bounce after curative brachytherapy for early-stage prostate cancer: A study of 274 African-Caribbean patients. Leduc N; Atallah V; Creoff M; Rabia N; Taouil T; Escarmant P; Vinh-Hung V Brachytherapy; 2015; 14(6):826-33. PubMed ID: 26489920 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]